What is Diabetic Retinopathy?
Diabetic retinopathy (DR) is a microvascular complication of diabetes mellitus and the most common cause of preventable blindness in working-age adults worldwide. It results from chronic hyperglycaemia causing progressive damage to the retinal microvasculature.
Key Fact: DR affects approximately one-third of all people with diabetes. Nearly all patients with Type 1 DM will develop some degree of DR after 20 years.
The retina has the highest metabolic demand of any tissue per unit weight and is extremely vulnerable to ischaemia from microvascular disease.
Pathophysiology
The sequence of microvascular damage in DR follows a well-defined progression:
Early Changes
- Pericyte loss — first structural change; pericytes support capillary integrity
- Basement membrane thickening — increases permeability
- Microaneurysms — earliest clinically visible sign; dot-like outpouchings
- Dot and blot haemorrhages — small intraretinal bleeds
Progressive Changes
- Hard exudates — lipid/protein leakage; yellow deposits with sharp borders
- Cotton wool spots — soft exudates; nerve fibre layer infarcts (fluffy white patches)
- Venous beading / IRMA — intraretinal microvascular abnormalities; pre-proliferative sign
- Neovascularisation — new fragile vessels driven by VEGF
Biochemical Mechanisms: Chronic hyperglycaemia activates aldose reductase (polyol pathway), PKC pathway, AGE formation, and oxidative stress — all damaging pericytes and endothelial cells.
Classification of Diabetic Retinopathy
| Classification | Features | Risk of Progression to PDR |
|---|---|---|
| Mild NPDR | Microaneurysms only | 5% per year |
| Moderate NPDR | Microaneurysms + dot/blot haemorrhages + hard exudates + cotton wool spots | 12–27% per year |
| Severe NPDR | 4-2-1 rule: haemorrhages in 4 quadrants OR venous beading in 2 quadrants OR IRMA in 1 quadrant | 52% within 1 year |
| PDR | Neovascularisation (NVD = disc; NVE = elsewhere) ± vitreous haemorrhage ± traction RD | High risk of severe vision loss |
| Diabetic Maculopathy | Oedema/exudates at macula; most common cause of visual loss in T2DM | N/A — separate classification |
NPDR vs PDR: Non-proliferative DR = vascular changes without new vessel growth. Proliferative DR = neovascularisation present (driven by hypoxia-induced VEGF release).
Diabetic Maculopathy
Diabetic maculopathy is the most common cause of visual loss in Type 2 diabetes. It can occur at any stage of DR.
Types
- Focal maculopathy — well-defined rings of hard exudates at macula
- Diffuse maculopathy — widespread oedema; worse prognosis
- Ischaemic maculopathy — capillary non-perfusion; poor prognosis
- Mixed maculopathy — combination of above
Diabetic Macular Oedema (DMO)
- Fluid accumulation in macula due to breakdown of blood-retinal barrier
- Diagnosed by OCT (gold standard for DMO thickness)
- Clinically significant macular oedema (CSME) = retinal thickening within 500 microns of fovea
- Now treated with anti-VEGF as first-line
Visual Symptoms — RED FLAGS
EMERGENCY — Refer Same Day: Sudden painless vision loss in a known diabetic patient = vitreous haemorrhage until proven otherwise. Requires urgent ophthalmology review.
Symptoms by Stage
- Early NPDR: Usually asymptomatic (hence screening is critical)
- Floaters: Classic symptom of vitreous haemorrhage (PDR)
- Blurred central vision: Macular oedema / maculopathy
- Distorted vision (metamorphopsia): Macular involvement
- Sudden painless vision loss: Vitreous haemorrhage or traction retinal detachment
Nursing Visual Assessment
- Visual acuity (Snellen chart) — document both eyes separately
- Date of last ophthalmology review
- Compliance with screening appointments
- History of laser/anti-VEGF treatment
- Changes in vision since last assessment
- Amsler grid test for macular distortion
Screening Programme
Annual DR screening is the cornerstone of prevention of blindness. The aim is to detect DR before symptoms develop.
Dilated Fundoscopy
Indirect ophthalmoscopy after pupil dilation (tropicamide). Gold standard for detailed examination.
Digital Retinal Photography
7-field stereoscopic photography. Allows grading by trained graders. Widely used in national programmes.
OCT
Optical Coherence Tomography — gold standard for diagnosing and monitoring diabetic macular oedema. Quantifies retinal thickness.
Screening Frequency
- Type 1 DM: Screen 5 years after diagnosis onset (not before puberty)
- Type 2 DM: Screen at diagnosis, then annually
- Pregnancy with pre-existing diabetes: Screen at booking and 28 weeks (higher risk)
- Accelerate to 6-monthly if moderate NPDR detected
Associated Risk Factors Assessment
Nurses must assess modifiable risk factors that accelerate DR progression:
Glycaemic Control
- HbA1c — target <7% (53 mmol/mol) for most patients
- Duration of diabetes (strongest predictor)
- Frequency of hypoglycaemia (rapid correction worsens DR acutely — "early worsening")
Systemic Risk Factors
- Blood pressure — target <130/80 mmHg
- Dyslipidaemia (hard exudates correlate with elevated LDL)
- Nephropathy (microalbuminuria = parallel microvascular damage)
- Anaemia (exacerbates retinal ischaemia)
- Pregnancy (accelerates all stages)
- Smoking cessation counselling
Treatment Pyramid — Most Important First
Priority 1 — MOST IMPORTANT: Tight glycaemic control (HbA1c <7%) AND blood pressure control (<130/80 mmHg). UKPDS and DCCT trials demonstrated these reduce risk of DR development and progression by up to 76%.
Treatment depends on stage of DR and whether maculopathy is present:
| Stage | Treatment | Nursing Role |
|---|---|---|
| Mild–Moderate NPDR | Optimise HbA1c + BP + lipids; annual review | Medication compliance support; lifestyle education |
| Severe NPDR | Urgent ophthalmology review; consider PRP laser | Fast-track referral; patient education |
| PDR | Panretinal photocoagulation (PRP) laser; anti-VEGF adjunct | Post-procedure care; dark adaptation education |
| Diabetic Macular Oedema (DMO) | Anti-VEGF injections (first-line); focal/grid laser (second-line) | Intravitreal injection preparation and aftercare |
| Vitreous Haemorrhage / Traction RD | Vitrectomy surgery | Pre/post-op care; posturing instructions |
Laser Photocoagulation
Panretinal Photocoagulation (PRP)
- Indicated for PDR and severe NPDR
- 1,200–1,600 laser burns applied to peripheral retina
- Destroys ischaemic peripheral retina → reduces VEGF drive → regression of new vessels
- Side effects: reduced night vision, visual field loss, temporary blurring
- May require 2–3 sessions
Focal / Grid Laser (Maculopathy)
- Focal: direct treatment of leaking microaneurysms
- Grid: for diffuse macular oedema
- Second-line — largely superseded by anti-VEGF for DMO
- Still used in ischaemic maculopathy where anti-VEGF less effective
Anti-VEGF Therapy — Now First-Line for DMO
Intravitreal anti-VEGF injections have revolutionised DMO treatment and are superior to laser for vision outcomes.
Ranibizumab (Lucentis)
Monthly intravitreal injection. NICE approved for DMO. Anti-VEGF-A Fab fragment.
Bevacizumab (Avastin)
Off-label use. Full-length anti-VEGF antibody. Widely used due to lower cost — common in GCC public hospitals.
Aflibercept (Eylea)
Binds VEGF-A, VEGF-B, and PIGF. Every-8-week dosing after loading. Preferred in centre-involving DMO.
Nursing Role in Intravitreal Injections
- Prepare sterile field and equipment (slit lamp / theatre setting)
- Administer topical anaesthetic and povidone-iodine 5% before injection
- Post-injection: check IOP at 30 minutes; instruct patient on symptoms of endophthalmitis
- Educate: redness/grittiness normal 24–48 hours; floaters may indicate vitreous haemorrhage — seek urgent review
- Document lot number and injection details in patient record
Vitrectomy
Surgical intervention for advanced PDR complications:
- Indications: Non-clearing vitreous haemorrhage (>3 months), traction retinal detachment involving macula, combined traction/rhegmatogenous RD
- Procedure: Pars plana vitrectomy — removes vitreous gel, membranes, and treats underlying retina
- Post-op nursing: Posturing (face down if gas tamponade used — up to 10 days); monitor for raised IOP; avoid air travel with gas bubble
- Silicone oil: May be used instead of gas — must be removed at second surgery
Nursing Management — Holistic Care
Medication Compliance
- Support adherence to antidiabetic medications (metformin, insulin, GLP-1 agonists)
- ACE inhibitors / ARBs for BP and renoprotection
- Statins for dyslipidaemia
- Fenofibrate — evidence for slowing DR progression independent of lipid-lowering
Patient Education
- Importance of annual eye screening even with good vision
- Report any sudden vision change immediately
- Do not drive after dilated fundoscopy (blur lasts 4–6 hours)
- Home blood glucose monitoring targets
- Smoking cessation — accelerates DR
Emotional Support: Vision loss is devastating. Nurses should acknowledge psychological impact, involve sight-loss charities, and refer to diabetic support groups. In GCC, language-appropriate education materials are essential.
Vitreous Haemorrhage
Bleeding into the vitreous from fragile neovascular vessels in PDR.
- Presentation: Sudden painless vision loss; floaters or "red haze"; may see red reflex loss on fundoscopy
- Management: Urgent ophthalmology; B-scan ultrasound if retina not visible; observe 1–3 months for spontaneous resolution; vitrectomy if non-clearing
- Nursing action: Semi-recumbent positioning (gravity settles blood inferiorly); avoid anticoagulants if possible; educate on no heavy lifting/straining (Valsalva)
Traction Retinal Detachment
Fibrovascular proliferative membranes from PDR contract, pulling the retina off the RPE (retinal pigment epithelium).
Surgical Emergency: If macula-involving traction RD detected — urgent vitrectomy required to preserve central vision. Macula-off RD = worse visual prognosis.
- May be asymptomatic until macula involved
- U-scan / B-scan ultrasound to assess extent
- Post-vitrectomy: face-down posturing for gas tamponade (nurse-supervised in hospital)
Neovascular Glaucoma (NVG)
- Iris neovascularisation (rubeosis iridis) → blocks trabecular meshwork → raised IOP → severe painful vision loss
- Treatment: anti-VEGF + PRP laser to regress new vessels; glaucoma surgery (trabeculectomy / drainage tube)
- Nursing: monitor IOP; pain management; topical antihypertensives
Early Worsening of DR
Clinical Pearl: Rapid improvement in glycaemic control (e.g., starting insulin intensification, or after bariatric surgery) can paradoxically worsen DR in the short term. Mechanism: altered retinal blood flow and IGF-1 changes. Monitor closely for 12 months.
GCC-Specific Context
The GCC region has among the highest rates of Type 2 diabetes globally, creating a major burden of DR.
Epidemiology: UAE has a T2DM prevalence of approximately 19% — one of the highest in the world (IDF Atlas). KSA prevalence ~18%. Bahrain, Kuwait, Qatar, Oman all exceed global averages.
National Screening Programmes in GCC ▼
- UAE / DHA: Dubai Health Authority mandates annual diabetic retinopathy screening for all registered diabetic patients. Digital retinal photography programme in all DHA primary care clinics.
- Abu Dhabi / DOH: SEHA network runs DR screening; telemedicine grading programmes expanding.
- KSA: SCFHS-aligned diabetic care pathways; Vision 2030 health transformation includes diabetic screening.
- Qatar: Hamad Medical Corporation runs dedicated diabetic eye service; QCHP-registered nurses coordinate screening lists.
- Bahrain: NHRA oversees chronic disease management; DR screening in polyclinics.
Ramadan and Diabetic Retinopathy ▼
Ramadan poses specific challenges for patients with DR:
- Blood glucose fluctuations during fasting hours → risk of hypoglycaemia and post-iftar hyperglycaemia
- Dehydration increases blood viscosity → worsens retinal ischaemia
- Medication timing must be adjusted — nurses counsel patients pre-Ramadan
- Patients with active PDR or recent vitreous haemorrhage advised against fasting by most GCC diabetologists
- Missing eye clinic appointments during Ramadan common — nurse-led reminder systems important
Late Presentation — Cultural and Awareness Factors ▼
- DR is painless and asymptomatic until advanced — patients may not present until significant vision loss
- Cultural tendency in some GCC communities to minimise symptoms or rely on traditional medicine first
- Language barriers for expatriate workforce (South Asian, Filipino, African) — use professional interpreters and multilingual printed materials
- Stigma around blindness — emphasise that screening prevents blindness, not just detects disease
- Fear of treatment (laser, injections) causes avoidance — nurse education critical
Nursing Practice in GCC Ophthalmic Settings ▼
- GCC hospitals run high-volume intravitreal injection clinics — nurses prepare and assist with 20–50 injections per session
- DHA exam commonly tests: anti-VEGF agents, PRP indications, screening intervals
- Nurses coordinate between diabetology, ophthalmology, and primary care — holistic DM management
- Telemedicine DR screening expanding in remote areas of Oman and Saudi Arabia
- Expatriate construction workers with undiagnosed T2DM — screening in occupational health settings
High-Yield Exam Facts
- DR = most common cause of blindness in working-age adults
- Diabetic maculopathy = most common cause of visual loss in T2DM
- Cotton wool spots = nerve fibre layer infarcts (NOT hard exudates)
- Hard exudates = lipid/protein deposits; sharp borders
- First clinically visible sign = microaneurysms
- PDR = neovascularisation present (NVD or NVE)
- Severe NPDR = 4-2-1 rule
- Anti-VEGF = first-line for DMO (replaced focal laser)
- PRP laser = treatment for PDR and severe NPDR
- OCT = gold standard for diagnosing and monitoring DMO
- Vitrectomy = vitreous haemorrhage not clearing or traction RD
- Tight glycaemic control = most important preventive measure
- Rapid HbA1c improvement can cause early worsening of DR
- Annual dilated fundoscopy for all T2DM from diagnosis
Practice MCQs
Q1. A 45-year-old patient with 15-year history of T2DM presents with sudden painless vision loss and floaters in the right eye. The most likely diagnosis is:
A. Acute angle-closure glaucoma
B. Vitreous haemorrhage secondary to proliferative diabetic retinopathy
C. Diabetic macular oedema
D. Hypertensive retinopathy
Correct. Sudden painless vision loss with floaters in a long-standing diabetic = vitreous haemorrhage from neovascular vessels in PDR. This is a same-day ophthalmology emergency.
Q2. Which treatment is currently considered first-line for centre-involving diabetic macular oedema?
A. Panretinal photocoagulation laser
B. Focal/grid laser photocoagulation
C. Intravitreal anti-VEGF injection
D. Oral fenofibrate
Correct. Anti-VEGF agents (ranibizumab, aflibercept, bevacizumab) are now first-line for centre-involving DMO, demonstrating superior visual outcomes compared to laser in major RCTs (RISE, RIDE, PROTOCOL T).
Q3. A diabetic patient's fundoscopy shows haemorrhages in all 4 quadrants without neovascularisation. This represents:
A. Mild NPDR
B. Severe NPDR
C. Early PDR
D. Moderate NPDR
Correct. Severe NPDR is defined by the 4-2-1 rule: haemorrhages in 4 quadrants OR venous beading in 2 quadrants OR IRMA in 1 quadrant. No neovascularisation means it is not yet PDR.
Q4. A nurse is preparing a patient for an intravitreal injection. Which step is MOST important to prevent endophthalmitis?
A. Applying topical steroid drops 30 minutes before
B. Asking the patient to fast for 4 hours
C. Applying 5% povidone-iodine to conjunctival sac before injection
D. Administering systemic antibiotics post-procedure
Correct. Povidone-iodine 5% applied to the conjunctival sac immediately before intravitreal injection is the single most important step to prevent endophthalmitis — the most serious complication of intravitreal injection.
Common Exam Traps
- Cotton wool spots vs hard exudates: Cotton wool = soft, fluffy, white; nerve fibre infarcts. Hard exudates = yellow, sharp borders; lipid deposits.
- NPDR vs PDR distinction: Only neovascularisation makes it PDR — not the severity of haemorrhages alone.
- Maculopathy in T2DM: Most common cause of visual loss in T2DM is maculopathy, NOT PDR.
- Screening in T1DM: Start screening 5 years after diagnosis — not at diagnosis (DR doesn't develop in first 5 years of T1DM).
- Treatment priority: Questions asking "what is MOST important" — always glycaemic and BP control first, before any ophthalmic procedure.